Illumina products for cystic fibrosis testing are FDA-cleared and validated to meet stringent performance criteria for molecular diagnostics. Our next-generation sequencing (NGS) assays provide visibility into the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Ultimately, this information can be used to make informed family planning decisions and choose optimized treatments, potentially leading to a better quality of life.
Clinical laboratories can develop their own next-generation sequencing (NGS) assays for the MiSeqDx instrument using the TruSeq Custom Amplicon Kit Dx. This amplicon sequencing solution lets molecular diagnostics labs develop assays using oligonucleotide probes they have designed on their own.
This provides users with the flexibility to target specific regions of interest and better meet the needs of their customers.
2 hr 10 min hands-on
Develop your own diagnostic tests.
In partnership with pharmaceutical companies and the oncology community, we are developing companion diagnostic tests that detect biomarkers linked to disease to allow for appropriate treatment decisions.
The Extended RAS Panel is the first FDA-approved NGS-based companion diagnostic for RAS mutational testing in colorectal cancer to determine eligibility for Vectibix® treatment.* We intend to expand the menu of clinical assays offered on the MiSeqDx System, ultimately leading to more effective targeted therapies.
*Vectibix is a registered trademark of Amgen, Inc.
3 hr hands-on
The first FDA-approved NGS-based in vitro diagnostic for colorectal cancer for use in establishing eligibility of patients for treatment with Vectibix®.
10 min hands-on
Load-and-go, automated sequencing.
In Research mode on the MiSeqDx System, you can access any application or method that can be done on the MiSeq System. Perform targeted gene, small genome, and amplicon sequencing, as well as 16S metagenomics and targeted gene expression analysis.See All MiSeq Research Applications